TY - JOUR
T1 - The role of myostatin and bone morphogenetic proteins in muscular disorders
AU - Tsuchida, Kunihiro
N1 - Funding Information:
The author would like to acknowledge the helpful discussions with Drs S Takeda, Y Sunada, A McPherron, SJ Lee, H Sugino, S Noji and M Nakatani. This work was supported by a grant (16B-2) for Nervous and Mental Disorders, and a grant (17231401) for Research on Psychiatric and Neurological Diseases and Mental Health, both from the Ministry of Health, Labour and Welfare; a research grant from Priority Area Research Programme of the Ministry of Education, Culture, Sports, Science and Technology of Japan (adipomics); a grant from the Sankyo Foundation of Life Science; and grants from Fujita Health University.
PY - 2006/2
Y1 - 2006/2
N2 - Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.
AB - Skeletal muscle is the largest organ in the human body, and plays an important role in body movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as muscular dystrophy, muscle wasting and ageing. Chemicals and proteins that restore muscle mass and function are potential drugs that can improve human health and could be used in the clinic. Myostatin is a muscle-specific member of the transforming growth factor (TGF)-β superfamily that plays an essential role in the negative regulation of muscle growth. Inhibition of myostatin activity is a promising therapeutic method for restoring muscle mass and strength. Potential inhibitors of myostatin include follistatin domain-containing proteins, myostatin propeptide, myostatin antibodies and chemical compounds. These inhibitors could be beneficial for the development of clinical drugs for the treatment of muscular disorders. Bone morphogenetic protein (BMP) plays a significant role in the development of neuromuscular architecture and its proper functions. Modulation of BMP activity could be beneficial for muscle function in muscular disorders. This review will describe the current progress in therapy for muscular disorders, emphasising the importance of myostatin as a drug target.
UR - http://www.scopus.com/inward/record.url?scp=32944469015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944469015&partnerID=8YFLogxK
U2 - 10.1517/14712598.6.2.147
DO - 10.1517/14712598.6.2.147
M3 - Review article
C2 - 16436040
AN - SCOPUS:32944469015
SN - 1471-2598
VL - 6
SP - 147
EP - 154
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 2
ER -
